Article
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
Molecular pharmaceutics - 6 Sept 2021
Zhang Zhe, Wang Xiaobo, Ye Jiajun, Liu Huanhuan, Fang Jianyang, Zhang Mingru, Li Yesen, Huang Jinxiong, Zhang Deliang, Wang Jing, Zhang Xianzhong
Abstract excerpt
Although KRAS has been an important target for many cancers, direct inhibition of oncogenic RAS remains challenging. Until recently, covalent KRAS G12C-specific inhibitors have been developed and progressed to the clinics. Nevertheless, not all patients benefit from these covalent inhibitors. At present, identification of candidates for this treatment requires tissue biopsies and gene sequencing, which are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.